Literature DB >> 14997049

Differentiation between cancerous and normal hyperplastic lobules in breast lesions.

Michael Slater1, Suzanne Danieletto, Margaret Pooley, Liew Cheng Teh, Angus Gidley-Baird, Julian A Barden.   

Abstract

Determining the risk that a particular area of hyperplastic breast tissue will progress to cancer is difficult and is currently expressed only as a general risk factor within the population. Using an antibody against the apoptotic purinergic receptor P2X7, we examined 40 cases each of the following histological categories: normal, moderate, florid and atypical hyperplasia, lobular carcinoma in situ, ductal carcinoma in situ, invasive lobular and invasive ductal carcinoma. These were previously diagnosed by H&E and supplied by clinical laboratories as tissue sections. Normal and mildly hyperplastic epithelium was devoid of the cytolytic P2X7 receptors whereas all epithelial cells in all cases of in situ or invasive lobular or ductal carcinoma labelled intensely. The lobular and ductal in situ cases labelled intracellularly while the invasive epithelial cancer cells showed intense cell surface label indicating an attempt was being made to induce apoptosis. All these receptors however are non-functional and thus unable to induce apoptosis. Approximately 10% of all hyperplastic lobules examined in the biopsied tissue, regardless of H&E classification, labelled for P2X7, which is suggestive of early metabolic cancerous change. The acini within lobules were either completely labelled with P2X7 or were completely devoid of the receptor. A potential advantage of this method lies in identifying early cancerous change in hyperplastic lobules and in establishing the true extent of cancerous spread in infiltrating lesions, thus facilitating the task of reporting clear surgical margins.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14997049     DOI: 10.1023/B:BREA.0000010670.85915.0f

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

Review 1.  New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors.

Authors:  Ross Corriden; Paul A Insel
Journal:  Purinergic Signal       Date:  2012-04-15       Impact factor: 3.765

2.  Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma.

Authors:  Li-Qun Gu; Feng-Ying Li; Lin Zhao; Yun Liu; Qian Chu; Xun-Xiong Zang; Jian-Min Liu; Guang Ning; Yong-Ju Zhao
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

Review 3.  The P2X7 Receptor in the Maintenance of Cancer Stem Cells, Chemoresistance and Metastasis.

Authors:  Vanessa Fernandes Arnaud-Sampaio; Izadora Lorrany Alves Rabelo; Henning Ulrich; Claudiana Lameu
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

Review 4.  Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.

Authors:  Tamás Deli; László Csernoch
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

5.  P2X(7) receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin.

Authors:  Xin Li; Xiaoping Qi; Lingyin Zhou; Wen Fu; Fadi W Abdul-Karim; Gregory Maclennan; George I Gorodeski
Journal:  Purinergic Signal       Date:  2009-04-28       Impact factor: 3.765

6.  P2X(7): a growth-promoting receptor-implications for cancer.

Authors:  Francesco Di Virgilio; Davide Ferrari; Elena Adinolfi
Journal:  Purinergic Signal       Date:  2009-03-04       Impact factor: 3.765

7.  Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis.

Authors:  Elena Adinolfi; Maria Giulia Callegari; Maria Cirillo; Paolo Pinton; Carlotta Giorgi; Dario Cavagna; Rosario Rizzuto; Francesco Di Virgilio
Journal:  J Biol Chem       Date:  2009-02-09       Impact factor: 5.157

8.  Autocrine signaling via release of ATP and activation of P2X7 receptor influences motile activity of human lung cancer cells.

Authors:  Erina Takai; Mitsutoshi Tsukimoto; Hitoshi Harada; Shuji Kojima
Journal:  Purinergic Signal       Date:  2014-03-14       Impact factor: 3.765

Review 9.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

Review 10.  Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer.

Authors:  Matthew Drill; Nigel C Jones; Martin Hunn; Terence J O'Brien; Mastura Monif
Journal:  Purinergic Signal       Date:  2021-03-17       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.